First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection

Williams, Eleri J., Gray, Joanne, Luck, Suzanne, Atkinson, Claire, Embleton, Nicholas D., Kadambari, Seilesh, Davis, Adrian, Griffiths, Paul, Sharland, Mike, Berrington, Janet E. and Clark, Julia E. (2015) First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection. Archives of Disease in Childhood-Fetal and Neonatal Edition, 100 6: F501-F506. doi:10.1136/archdischild-2014-306756


Author Williams, Eleri J.
Gray, Joanne
Luck, Suzanne
Atkinson, Claire
Embleton, Nicholas D.
Kadambari, Seilesh
Davis, Adrian
Griffiths, Paul
Sharland, Mike
Berrington, Janet E.
Clark, Julia E.
Title First estimates of the potential cost and cost saving of protecting childhood hearing from damage caused by congenital CMV infection
Journal name Archives of Disease in Childhood-Fetal and Neonatal Edition   Check publisher's open access policy
ISSN 1359-2998
Publication date 2015-11
Sub-type Article (original research)
DOI 10.1136/archdischild-2014-306756
Open Access Status Not Open Access
Volume 100
Issue 6
Start page F501
End page F506
Total pages 6
Place of publication London, United Kingdom
Publisher B M J Group
Collection year 2016
Language eng
Formatted abstract
Background: Congenital cytomegalovirus (cCMV) is an important cause of childhood deafness, which is modifiable if diagnosed within the first month of life. Targeted screening of infants who do not pass their newborn hearing screening tests in England is a feasible approach to identify and treat cases to improve hearing outcome.

Aims: To conduct a cost analysis of targeted screening and subsequent treatment for cCMV-related sensorineural hearing loss (SNHL) in an, otherwise, asymptomatic infant, from the perspective of the UK National Health Service (NHS).

Methods: Using data from the newborn hearing screening programme (NHSP) in England and a recent study of targeted screening for cCMV using salivary swabs within the NHSP, we estimate the cost (in UK pounds (£)) to the NHS. The cost of screening (time, swabs and PCR), assessing, treating and following up cases is calculated. The cost per case of preventing hearing deterioration secondary to cCMV with targeted screening is calculated.

Results: The cost of identifying, assessing and treating a case of cCMV-related SNHL through targeted cCMV screening is estimated to be £6683. The cost of improving hearing outcome for an infant with cCMV-related SNHL through targeted screening and treatment is estimated at £14 202.

Conclusions: The costs of targeted screening for cCMV using salivary swabs integrated within NHSP resulted in an estimate of cost per case that compares favourably with other screening programmes. This could be used in future studies to estimate the full economic value in terms of incremental costs and incremental health benefits.
Keyword Cytomegalovirus-Infection
Cochlear Implantation
Children
Population
Prevalence
Newborns
Outcomes
Disease
Saliva
Dna
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
School of Medicine Publications
Child Health Research Centre Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 29 Nov 2015, 00:26:52 EST by System User on behalf of Scholarly Communication and Digitisation Service